Impact fact

Thomas helps life sciences clients using biomedical data analytics and systems biology to drive innovation in drug discovery.


Thomas leads the European biomedical research service line at ZS, where he has established a science-led team that uses a combination of biological knowledge, deep data experience, and AI capabilities. This helps clients to achieve breakthrough discoveries, increase R&D outcomes and accelerate drug discovery. Thomas works with pharma and biotech companies to convert the wealth of omics data into novel insights at molecular, systemic and patient level. Furthermore, he helps clients establish scalable analytic capabilities to meet current and future demands for data-driven research and development.


Thomas’ expertise includes predictive science, research strategy and cross-discipline collaborations essential to leverage client capabilities and harness the exponential biomedical data growth. He has more than 20 years of experience delivering novel and tailored approaches to target discovery, precision medicine, drug repurposing and patient stratification. In addition, Thomas has experience working across various therapeutic areas utilizing structured, unstructured and emerging data types.

Prior experience

Thomas has led and grown teams establishing best practices for bioinformatics and data analytics, both in academia and industry. Thomas co-founded and served as CEO of Intomics, a deep data and AI company pioneering the use of multi-omics approaches and network biology in drug discovery. Danish bioinformatics and systems biology company, Intomics was acquired by ZS in 2022 to assist clients in pursuing breakthrough science and innovative medicines to improve patients’ lives.


Thomas holds a PhD in bioinformatics and systems biology and a Master of Science degree in chemical engineering, both from the Technical University of Denmark.

Media coverage